Chinese herbs containing aristolochic acid associated with renal failure and urothelial carcinoma: A review from epidemiologic observations to causal inference

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Yang, Hsiao Yu ^a,b   Chen, Pau Chung ^c,d   Wang, Jung Der ^e,f  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID; CARCINOGEN; STEROID; ARISTOLOCHIC ACID I; DNA ADDUCT; HERBACEOUS AGENT;

BELGIAN; CANCER RISK; CARCINOGENESIS; CHINESE HERB; DNA ADDUCT; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; FEMALE; FOLLOW UP; FOOD CONTAMINATION; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; KIDNEY INJURY; LABORATORY DIAGNOSIS; MICROALBUMINURIA; OBSERVATIONAL STUDY; OCCUPATIONAL EXPOSURE; REVIEW; STEROID THERAPY; TAIWAN; TRADITIONAL HEALER; TRANSITIONAL CELL CARCINOMA; URINARY EXCRETION; CARCINOMA; DRUG EFFECTS; PATHOLOGY; RENAL INSUFFICIENCY; UROTHELIUM;

ARISTOLOCHIC ACIDS; CARCINOGENS; CARCINOMA; DNA ADDUCTS; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; OCCUPATIONAL EXPOSURE; RENAL INSUFFICIENCY; TAIWAN; UROTHELIUM;

EID: 84919343909     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/569325     Document Type: Review

References (91)

1. Vanherweghem J.-L., Depierreux M., Tielemans C., Abramowicz D., Dratwa M., Jadoul M., Richard C., Vandervelde D., Verbeelen D., Vanhaelen-Fastre R., Vanhaelen M., Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. The Lancet 1993 341 8842 387 391 10.1016/0140-6736(93)92984-2 2-s2.0-0027512619
2. Nortier J. L., Martinez M. M., Schmeiser H. H., Arlt V. M., Bieler C. A., Petein M., Depierreux M. F., De Pauw L., Abramowicz D., Vereerstraeten P., Vanherweghem J., Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). The New England Journal of Medicine 2000 342 23 1686 1692 10.1056/NEJM200006083422301 2-s2.0-0034622082
3. Lin C. H., Yang C. S., Chinese herbs nephropathy Journal of Internal Medicine of Taiwan 2002 13 6 276 281 2-s2.0-0036942707
4. Vanhaelen M., Vanhaelen-Fastre R., But P., Vanherweghem J., Identification of aristolochic acid in Chinese herbs. The Lancet 1994 343, article 174 2-s2.0-0028147614
5. Yang C. S., Lin C. H., Chang S. H., Hsu H. C., Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. American Journal of Kidney Diseases 2000 35 2 313 318 10.1016/S0272-6386(00)70343-X 2-s2.0-0033969419
6. Chang C., Wang Y., Yang A., Chiang S., Rapidly progressive interstitial renal fibrosis associated with Chinese herbal medications. American Journal of Nephrology 2001 21 6 441 448 10.1159/000046647 2-s2.0-0035698245
7. Li X. B., Xing N. Z., Wang Y., Hu X., Yin H., Zhang X., Transitional cell carcinoma in renal transplant recipients: a single center experience. International Journal of Urology 2008 15 1 53 57 10.1111/j.1442-2042.2007.01932.x 2-s2.0-37848999709
8. Lord G. M., Cook T., Arlt V. M., Schmeiser H. H., Williams G., Pusey C. D., Urothelial malignant disease and Chinese herbal nephropathy. The Lancet 2001 358 9292 1515 1516 10.1016/S0140-6736(01)06576-X 2-s2.0-0035802716
9. Zhang C., Wang X., Shang M., Yu J., Xu Y., Li Z., Lei L., Li X., Cai S., Namba T., Simultaneous determination of five aristolochic acids and two aristololactams in Aristolochia plants by high-performance liquid chromatography. Biomedical Chromatography 2006 20 4 309 318 10.1002/bmc.565 2-s2.0-33646075104
10. Jong T. T., Lee M. R., Hsiao S. S., Hsai J., Wu T., Chiang S. T., Cai S., Analysis of aristolochic acid in nine sources of Xixin, a traditional Chinese medicine, by liquid chromatography/atmospheric pressure chemical ionization/tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2003 33 4 831 837 10.1016/S0731-7085(03)00310-8 2-s2.0-0242710000
11. Drew A. K., Whyte I. M., Bensoussan A., Dawson A. H., Zhu X., Myers S. P., Chinese herbal medicine toxicology database: monograph on herba asari, 'xi xin'. Journal of Toxicology 2002 40 2 169 172 10.1081/CLT-120004405 2-s2.0-0036310755
12. Lai M. N., Lai J. N., Chen P. C., Hsieh S. H., Hu F. C., Wang J. D., Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study. American Journal of Kidney Diseases 2010 55 3 507 518 10.1053/j.ajkd.2009.10.055 2-s2.0-77049088904
13. Lu J. R., Hsiao W. C., Does universal health insurance make health care unaffordable? Lessons from Taiwan. Health Affairs 2003 22 3 77 88 10.1377/hlthaff.22.3.77 2-s2.0-0038725711
14. Hsieh S. C., Lin I. H., Tseng W. L., Lee C. H., Wang J. D., Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003. Chinese Medicine 2008 3, article no. 13 10.1186/1749-8546-3-13 2-s2.0-56449129467
15. Yang H. Y., Lin J. L., Chen K. H., Yu C. C., Hsu P. Y., Lin C. L., Aristolochic acid-related nephropathy associated with the popular Chinese herb Xi Xin. Journal of Nephrology 2006 19 1 111 114 2-s2.0-33645462643
16. Hong Y. T., Fu L. S., Chung L. H., Hung S. C., Huang Y. T., Chi C. S., Fanconi's syndrome, interstitial fibrosis and renal failure by aristolochic acid in Chinese herbs. Pediatric Nephrology 2006 21 4 577 579 10.1007/s00467-006-0017-6 2-s2.0-33645354061
17. National Institute of Diabetes and Digestive and Kidney Diseases, U.S. Renal Data System, USRDS Annual Data Report: International Comparisons. 2006, http://www.usrds.org/
18. Collins A. J., Kasiske B., Herzog C., Excerpts from the United States renal data system 2004 annual data report: atlas of end-stage renal disease in the United States. American Journal of Kidney Diseases 2005 45 1, supplement 1 S1 S280
19. Neijing H.-D., The Yellow Emperor's Classic of Medicine 1995 Western Han Dynasty. (Chinese)
20. Cheng J. T., Review: drug therapy in Chinese traditional medicine. Journal of Clinical Pharmacology 2000 40 5 445 450 10.1177/00912700022009198 2-s2.0-0033673746
21. Lai M. N., Lai J. N., Chen P. C., Tseng W., Chen Y., Hwang J., Wang J., Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid. Nephrology 2009 14 2 227 234 10.1111/j.1440-1797.2008.01061.x 2-s2.0-64049117979
22. Lai M. N., Wang S. M., Chen P. C., Chen Y., Wang J., Population-based case-control study of chinese herbal products containing aristolochic acid and urinary tract cancer risk. Journal of the National Cancer Institute 2010 102 3 179 186 10.1093/jnci/djp467 2-s2.0-76349101626
23. Chang C.-H., Yang C.-M., Yang A.-H., Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan. Cancer 2007 109 8 1487 1492 10.1002/cncr.22557 2-s2.0-34247160849
24. Wang T. Y., Hu C. J., Kuo C. W., Chen Y., Lin J., Yang C., Yen T., High incidence and recurrence of transitional cell carcinoma in Taiwanese patients with end-stage renal disease. Nephrology 2011 16 2 225 231 10.1111/j.1440-1797.2010.01366.x 2-s2.0-79551527317
25. Wang S. M., Lai M. N., Chen P. C., Increased risk of urothelial cancer in young and middle aged patients with end-stage renal disease. Journal of the Formosan Medical Association 2013 10.1016/j.jfma.2013.10.022
26. Wang S. M., Lai M. N., Wei A., Increased risk of urothelial cancer in young and middle aged patients with end-stage renal disease. PloS ONE 2013 10.1016/j.jfma.2013.10.022
27. Wang S. M., Lai M. N., Chen P. C., Increased upper and lower tract urothelial carcinoma in patients with end stage renal disease: a nationalwide cohort study in Taiwan during 1997-2008. BioMed Research International 2014 2014 9 149750 10.1155/2014/149750
28. Chi C., Lee J. L., Lai J. S., Chen C. Y., Chang S. K., Chen S. C., The practice of Chinese medicine in Taiwan. Social Science and Medicine 1996 43 9 1329 1348 10.1016/0277-9536(95)00429-7 2-s2.0-0030430979
29. Yang H. Y., Wang J. D., Lo T. C., Chen P. C., Increased Mortality risk for cancers of the kidney and other urinary organs among Chinese herbalists. Journal of Epidemiology 2009 19 1 17 23 10.2188/jea.JE20080035 2-s2.0-60549116138
30. Yang H. Y., Wang J. D., Lo T. C., Chen P. C., Increased risks of upper tract urothelial carcinoma in male and female Chinese herbalists. Journal of the Formosan Medical Association 2011 110 3 161 168 10.1016/S0929-6646(11)60026-0 2-s2.0-79955612144
31. Yang H. Y., Wang J. D., Lo T. C., Chen P. C., Occupational kidney disease among Chinese herbalists exposed to herbs containing aristolochic acids. Occupational and Environmental Medicine 2011 68 4 286 290 10.1136/oem.2010.058594 2-s2.0-79952574878
32. Yang H. Y., Wang J. D., Lo T. C., Chen P. C., Occupational exposure to herbs containing aristolochic acids increases the risk of urothelial carcinoma in Chinese herbalists. Journal of Urology 2013 189 1 48 52 10.1016/j.juro.2012.08.090 2-s2.0-84870903611
33. Chernozemsky I. N., Stoyanov I. S., Petkova-Bocharova T. K., Nicolov I. G., Draganov I. V., Stoichev I. I., Tanchev Y., Naidenov D., Kalcheva N. D., Geographic correlation between the occurrence of endemic nephropathy and urinary tract tumours in Vratza district, Bulgaria. International Journal of Cancer 1977 19 1 1 11 10.1002/ijc.2910190102 2-s2.0-0017353604
34. Debelle F. D., Vanherweghem J., Nortier J. L., Aristolochic acid nephropathy: a worldwide problem. Kidney International 2008 74 2 158 169 10.1038/ki.2008.129 2-s2.0-41549102309
35. Grollman A. P., Jelaković B., Role of environmental toxins in endemic (Balkan) nephropathy. Journal of the American Society of Nephrology 2007 18 11 2817 2823 10.1681/ASN.2007050537 2-s2.0-35948966844
36. Schmeiser H. H., Bieler C. A., Wiessler M., Van Ypersele De Strihou C., Cosyns J., Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Research 1996 56 9 2025 2028 2-s2.0-0029983768
37. Cosyns J. P., Jadoul M., Squifflet J. P., Wese F., De Strihou C. V. Y., Urothelial lesions in Chinese-herb nephropathy. American Journal of Kidney Diseases 1999 33 6 1011 1017 10.1016/S0272-6386(99)70136-8 2-s2.0-0033011129
38. Jelaković B., Karanović S., Vuković-Lela I., Miller F., Edwards K. L., Nikolić J., Tomić K., Slade N., Brdar B., Turesky R. J., Stipancić Ž., Dittrich D., Grollman A. P., Dickman K. G., Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney International 2012 81 6 559 567 10.1038/ki.2011.371 2-s2.0-84857765122
39. Wu C. F., Pang S. T., Shee J. J., Chang P., Chuang C., Chen C., Liao S., Weng W., Identification of genetic alterations in upper urinary tract urothelial carcinoma in end-stage renal disease patients. Genes Chromosomes and Cancer 2010 49 10 928 934 10.1002/gcc.20803 2-s2.0-77957875134
40. Poon S. L., Pang S. T., McPherson J. R., Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Science Translational Medicine 2013 5 197ra01
41. Chen C. H., Dickman K. G., Moriya M., Zavadil J., Sidorenko V. S., Edwards K. L., Gnatenko D. V., Wu L., Turesky R. J., Wu X., Pu Y., Grollman A. P., Aristolochic acid-associated urothelial cancer in Taiwan. Proceedings of the National Academy of Sciences of the United States of America 2012 109 21 8241 8246 10.1073/pnas.1119920109 2-s2.0-84861428636
42. Lebeau C., Debelle F. D., Arlt V. M., Pozdzik A., De Prez E. G., Phillips D. H., Deschodt-Lanckman M. M., Vanherweghem J., Nortier J. L., Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. Nephrology Dialysis Transplantation 2005 20 11 2321 2332 10.1093/ndt/gfi042 2-s2.0-27644597566
43. Pozdzik A. A., Salmon I. J., Debelle F. D., Decaestecker C., Van Den Branden C., Verbeelen D., Deschodt-Lanckman M. M., Vanherweghem J.-., Nortier J. L., Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney International 2008 73 5 595 607 10.1038/sj.ki.5002714 2-s2.0-39349086390
44. Debelle F. D., Nortier J. L., de Prez E. G., Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. Journal of the American Society of Nephrology 2002 13 2 431 436 2-s2.0-0036151616
45. Yang L., Li X., Wang H., Possible mechanisms explaining the tendency towards interstitial fibrosis in aristolochic acid-induced acute tubular necrosis. Nephrology Dialysis Transplantation 2007 22 2 445 456 10.1093/ndt/gfl556 2-s2.0-33846678148
46. Stiborová M., Frei E., Breuer A., Bieler C. A., Schmeiser H. H., Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with chinese herbs nephropathy. Experimental and Toxicologic Pathology 1999 51 4-5 421 427 10.1016/S0940-2993(99)80033-5 2-s2.0-0032780946
47. Arlt V. M., Stiborova M., Schmeiser H. H., Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 2002 17 4 265 277 10.1093/mutage/17.4.265 2-s2.0-0036020624
48. Chen C. H., Dickman K. G., Moriya M., Zavadil J., Sidorenko V. S., Edwards K. L., Gnatenko D. V., Wu L., Turesky R. J., Wu X., Pu Y., Grollman A. P., Aristolochic acid-associated urothelial cancer in Taiwan. Proceedings of the National Academy of Sciences of the United States of America 2012 109 21 8241 8246 10.1073/pnas.1119920109 2-s2.0-84861428636
49. Fridman J. S., Lowe S. W., Control of apoptosis by p53. Oncogene 2003 22 56 9030 9040 10.1038/sj.onc.1207116 2-s2.0-1542353401
50. Lebeau C., Arlt V. M., Schmeiser H. H., Boom A., Verroust P. J., Devuyst O., Beauwens R., Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells. Kidney International 2001 60 4 1332 1342 10.1046/j.1523-1755.2001.00938.x 2-s2.0-0034791132
51. Gillerot G., Jadoul M., Arlt V. M., van Ypersele De Strihou C., Schmeiser H. H., But P. P., Bieler C. A., Cosyns J. P., Aristolochic acid nephropathy in a Chinese patient: time to abandon the term "Chinese herbs nephropathy"? American Journal of Kidney Diseases 2001 38 5 E26 10.1053/ajkd.2001.28624 2-s2.0-0035514681
52. Lemy A., Wissing K. M., Rorive S., Zlotta A., Roumeguere T., Muniz Martinez M., Decaestecker C., Salmon I., Abramowicz D., Vanherweghem J., Nortier J., Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. American Journal of Kidney Diseases 2008 51 3 471 477 10.1053/j.ajkd.2007.11.015 2-s2.0-39449104221
53. Hill A. B., The environment and disease: association or causation? Proceedings of the Royal Society of Medicine 1965 58 295 300 2-s2.0-31844443695
54. Rothman K. J., Greenland S., Causation and causal inference in epidemiology. The American Journal of Public Health 2005 95 1 S144 S150 10.2105/AJPH.2004.059204 2-s2.0-22744434433
55. International Agency for Research on Cancer, Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene 2002 82 IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. http://monographs.iarc.fr/ENG/Monographs/vol82/index.php
56. Yang L., Su T., Li X. M., Wang X., Cai S., Meng L., Zou W., Wang H., Aristolochic acid nephropathy: variation in presentation and prognosis. Nephrology Dialysis Transplantation 2012 27 1 292 298 10.1093/ndt/gfr291 2-s2.0-84863011301
57. Nortier J. L., Schmeiser H. H., Muniz Martinez M.-., Arlt V. M., Vervaet C., Garbar C. H., Daelemans P., Vabherweghem J., Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur without severe renal failure. Nephrology Dialysis Transplantation 2003 18 2 426 428 10.1093/ndt/18.2.426 2-s2.0-0037314789
58. Stewart G. D., Bariol S. V., Grigor K. M., Tolley D. A., McNeill S. A., A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. BJU International 2005 95 6 791 793 10.1111/j.1464-410X.2005.05402.x 2-s2.0-17444376390
59. Johansson S. L., Cohen S. M., Epidemiology and etiology of bladder cancer. Seminars in Surgical Oncology 1997 13 291 298
60. Djokic M., Hadzi-Djokic J., Nikolic J., Dragicevic D., Radivojevic D., Comparison of upper urinary tract tumours in the region of Balkan endemic nephropathy with urothelial tumours observed in other regions. Progres en Urologie 1999 9 1 61 68 2-s2.0-0347874906
61. Miletić-Medved M., Domijan A. M., Peraica M., Recent data on endemic nephropathy and related urothelial tumors in Croatia. Wiener Klinische Wochenschrift 2005 117 17 604 609 10.1007/s00508-005-0426-8 2-s2.0-26444601195
62. Stefanović V., Djukanović L., Čukuranović R., Bukvić D., Ležaić V., Marić I., Ogrizovic S. S., Jovanović I., Vlahovic P., Pešić I., Djordjević V., Beta2-microglobulin and alpha1-microglobulin as markers of Balkan endemic nephropathy, a worldwide disease. Renal Failure 2011 33 2 176 183 552152 10.3109/0886022X.2011.552152 2-s2.0-79951975620
63. Chen D., Tang Z., Luo C., Chen H., Liu Z., Clinical and pathological spectrums of aristolochic acid nephropathy. Clinical Nephrology 2012 78 1 54 60 10.5414/CN107414 2-s2.0-84864538350
64. Nortier J. L., Vanherweghem J. L., Renal interstitial fibrosis and urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). Toxicology 2002 181-182 577 580 10.1016/S0300-483X(02)00486-9 2-s2.0-0037184789
65. Cosyns J. P., Aristolochic acid and "Chinese herbs nephropathy": a review of the evidence to date. Drug Safety 2003 26 1 33 48 10.2165/00002018-200326010-00004 2-s2.0-0037229943
66. Cosyns J. P., Jadoul M., Squifflet J., De Plaen J., Ferluga D., Van Ypersele De Strihou C., Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney International 1994 45 6 1680 1688 10.1038/ki.1994.220 2-s2.0-0028237221
67. Cosyns J. P., Dehoux J. P., Guiot Y., Goebbels R., Robert A., Bernard A. M., Van Ypersele De Strihou C., Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? Kidney International 2001 59 6 2164 2173 10.1046/j.1523-1755.2001.0590062164.x 2-s2.0-0035024391
68. Moriya M., Slade N., Brdar B., Medverec Z., Tomic K., Jelaković B., Wu L., Truong S., Fernandes A., Grollman A. P., TP53 Mutational signature for aristolochic acid: an environmental carcinogen. International Journal of Cancer 2011 129 6 1532 1536 10.1002/ijc.26077 2-s2.0-79960902308
69. Lord G. M., Hollstein M., Arlt V. M., Roufosse C., Pusey C. D., Cook T., Schmeiser H. H., DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. American Journal of Kidney Diseases 2004 43 4 e11 e17 10.1053/j.ajkd.2003.09.023 2-s2.0-2942513154
70. Schetter A. J., Harris C. C., Tumor suppressor p53 (TP53) at the crossroads of the exposome and the cancer genome. Proceedings of the National Academy of Sciences of the United States of America 2012 109 21 7955 7956 10.1073/pnas.1205457109 2-s2.0-84861448266
71. Vaclavik L., Krynitsky A. J., Rader J. I., Quantification of aristolochic acids I and II in herbal dietary supplements by ultra-high-performance liquid chromatography-multistage fragmentation mass spectrometry. Food Additives & Contaminants A, Chemistry, Analysis, Control, Exposure Risk Assessment 2014 31 5 784 791 10.1080/19440049.2014.892215
72. Yang Y., Chen J., Shi Y. P., Determination of aristolochic acid in urine using hollow fiber liquid-phase microextraction combined with high-performance liquid chromatography. Biomedical Chromatography 2010 24 12 1350 1355 10.1002/bmc.1448 2-s2.0-78449235869
73. Cai Z. W., Chan A. Y., Zhao Z. Z., Rapid and specific determination of DNA adducts for clinical diagnosis of poisoning and disease associated with aristolochic acid. Hong Kong Academy of Medicine 2013 19 supplement 9 40 43
74. Bieler C. A., Stiborova M., Wiessler M., Cosyns J., Van Ypersele De Strihou C., Schmeiser H. H., 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 1997 18 5 1063 1067 10.1093/carcin/18.5.1063 2-s2.0-0031284662
75. Yun B. H., Rosenquist T. A., Sidorenko V., Iden C. R., Chen C., Pu Y., Bonala R., Johnson F., Dickman K. G., Grollman A. P., Turesky R. J., Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry. Chemical Research in Toxicology 2012 25 5 1119 1131 10.1021/tx3000889 2-s2.0-84861325737
76. Guo L., Wu H., Yue H., Lin S., Lai Y., Cai Z., A novel and specific method for the determination of aristolochic acid-derived DNA adducts in exfoliated urothelial cells by using ultra performance liquid chromatography-triple quadrupole mass spectrometry. Journal of Chromatography B 2011 879 2 153 158 10.1016/j.jchromb.2010.11.035 2-s2.0-78651225249
77. Vanherweghem J. L. V., Abramowicz D., Tielemans C., Depierreux M., Effects of steroids on the progression of renal failure in chronic interstitial renal fibrosis: a pilot study in Chinese herbs nephropathy. The American Journal of Kidney Diseases 1996 27 2 209 215 10.1016/S0272-6386(96)90542-9 2-s2.0-0030021978
78. Chen W., Chen Y., Li A., The clinical and pathological manifestations of aristolochic acid nephropathy-the report of 58 cases. Zhonghua Yi Xue Za Zhi 2001 81 18 1101 1105 2-s2.0-0035949971
79. Zlotta A. R., Roumeguere T., Kuk C., Alkhateeb S., Rorive S., Lemy A., Van Der Kwast T. H., Fleshner N. E., Jewett M. A. S., Finelli A., Schulman C., Lotan Y., Shariat S. F., Nortier J., Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. European Urology 2011 59 6 1026 1031 10.1016/j.eururo.2011.03.027 2-s2.0-79955601707
80. Refik Gökmen M., Cosyns J., Arlt V. M., Stiborová M., Phillips D. H., Schmeiser H. H., Simmonds M. S. J., Cook H. T., Vanherweghem J., Nortier J. L., Lord G. M., The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Annals of Internal Medicine 2013 158 6 469 477 10.7326/0003-4819-158-6-201303190-00006 2-s2.0-84879985091
81. Wachtel-Galor S., Benzie I. F. F., Benzie I. F. F., Wachtel-Galor S., Herbal medicine: an introduction to its history, usage, regulation, current trends, and research needs. Herbal Medicine: Biomolecular and Clinical Aspects 2011 2nd Boca Raton, Fla, USA CRC Press
82. Wu K. M., Farrelly J. G., Upton R., Chen J., Complexities of the herbal nomenclature system in traditional Chinese medicine (TCM): lessons learned from the misuse of Aristolochia-related species and the importance of the pharmaceutical name during botanical drug product development. Phytomedicine 2007 14 4 273 279 10.1016/j.phymed.2006.05.009 2-s2.0-33847729819
83. Chuang M. S., Hsu Y. H., Chang C. C., Studies on adulteration and misusage of Asari radi in the market Annual Scientific Report of National Laboratories of Foods and Drugs, Taiwan R.O.C. 2003 21 153 167
84. Tung C. F., Ho Y. L., Tsai H. Y., Studies on the commonly misused and adulterated Chinese crude drug species in Taiwan China Medical College Journal 1999 8 35 46
85. Cheung T. P., Xue C., Leung K., Chan K., Li C., Aristolochic acids detected in some raw Chinese medicinal herbs and manufactured herbal products-a consequence of inappropriate nomenclature and imprecise labelling? Clinical Toxicology 2006 44 4 371 378 10.1080/15563650600671712 2-s2.0-33745685590
86. Liu C. T., Health care systems in transition II. Taiwan, Part I. A general overview of the health care system in Taiwan. Journal of Public Health Medicine 1998 20 1 5 10 2-s2.0-0031981122
87. Hsieh S. C., Lai J. N., Chen P. C., Chen H. J., Wang J. D., Development of active safety surveillance system for traditional Chinese medicine: an empirical study in treating climacteric women. Pharmacoepidemiology and Drug Safety 2006 15 12 889 899
88. Martena M. J., van der Wielen J. C. A., van de Laak L. F. J., Konings E. J. M., de Groot H. N., Rietjens I. M. C. M., Enforcement of the ban on aristolochic acids in Chinese traditional herbal preparations on the Dutch market. Analytical and Bioanalytical Chemistry 2007 389 1 263 275 10.1007/s00216-007-1310-3 2-s2.0-34548282054
89. Li Y., Tian M., Yu J., Shang M., Cai S., Studies on morphology and aristolochic acid analogue constituents of Asarum campaniflorum and a comparison with two official species of Asari Radix et Rhizoma. Journal of Natural Medicines 2010 64 4 442 451 10.1007/s11418-010-0433-6 2-s2.0-77956662041
90. Hwang J., Hur S. D., Seo Y. B., Mineralogical and chemical changes in pyrite after traditional processing for use in medicines. American Journal of Chinese Medicine 2004 32 6 907 919 10.1142/S0192415X0400251X 2-s2.0-10944228456
91. Chen Y. A., Hsu J. R., Ferng S. H., Tubulointerstitial nephritis-an under-recognized renal disease. Acta Nephrologica ROC 2007 21 11 16